Baricitinib and β Cell Function in Patients with New-Onset Type 1 Diabetes

In this Phase II, double-blind, randomized, placebo-controlled trial, scientists assigned patients with type 1 diabetes diagnosed during the previous 100 days to receive baricitinib or matched placebo orally for 48 weeks.